摘要
目的:探讨原发性肝癌(PHC)组织中表皮生长因子受体(EGFR)和基质金属蛋白酶MMP9的表达与术后复发或转移的关系。方法:选择24例临床Ⅱa期的PHC患者的手术切除标本,采用免疫组织化学方法检测PHC组织中EGFR和MMP9的表达情况。结果:PHC组织中EGFR和MMP9表达无关(r=0.059,P>0.05)。EGFR和MMP9共表达14例,术后(10.7±3.6)个月开始复发或转移;EGFR和MMP9单独表达9例,术后(25.5±3.2)个月开始复发或转移;1例2者均不表达,3a内未复发或转移;共表达与术后复发或转移时间之间存在负相关性(r=-0.702,P<0.01)。结论:EGFR和MMP9的共表达与PHC患者预后关系密切,可作为治疗方案的选择及预测复发转移的参考指标。
Aim： To investigate the relationship between the expression of EGFR,MMP9 and recurrence or metastasis of primary hepatocellular carcinoma （PHC） after operation. Methods： Using immunohistochemical staining method to study the expression of EGFR and MMP9 in tissue of 24 PHC cases at Ⅱ a phase. Results： The expression of EGFR had no correlation with that of MMP9（r =0.059,P 〉0.05）. Fourteen cases had coexpression of EGFR and MMP9 and the recurrent or metastatic time after operation was（0.7±3.6 ）months ;9 cases had single expression of EGFR or MMP9 and the recurrent or metastatic time was（25.5±3.2） months; 1 case without expression of EGFR or MMP9 had no recurrence or metastasis during 3 years after operation. The coexpression of EGFR and MMP9 was negatively correlated with recurrent or metastatic time（P 〈0.01 ,r = -0.702）. Conclusion： The coexpression of EGFR and MMP9 can be used to estimate the PHC prognosis.
出处
《郑州大学学报（医学版）》
CAS
北大核心
2005年第5期885-886,共2页
Journal of Zhengzhou University(Medical Sciences)
